Munich - Delayed Quote EUR

InflaRx NV (IF0.MU)

2.2000

-0.0920

(-4.01%)

At close: January 10 at 5:07:54 PM GMT+1

InflaRx Announces Participation in January Events in San Francisco

JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43rd Annual J.P. Morgan Healthcare Conference. LifeSci Partners Corporate Access Event1-on-1 meetings on January 14 and 15, 2025 Biotech Showc

GlobeNewswire 4 days ago

IFRX
US Penny Stocks To Watch In December 2024

As the U.S. stock market heads into the Christmas break, optimism is in the air with major indices like the Nasdaq Composite and S&P 500 posting gains, sparking hopes for a Santa Claus rally to close out 2024. Penny stocks may be considered a throwback term, yet they continue to offer intriguing opportunities for those looking beyond well-known names. Often representing smaller or newer companies, these stocks can provide growth potential at lower price points when supported by strong...

Simply Wall St. 18 days ago

ZDGE

AVIR

IFRX
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “We are pleased to have started our Phase

GlobeNewswire 22 days ago

IFRX
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?

We recently compiled a list of the 10 Best German Stocks To Buy Now. In this article, we are going to take a look at where InflaRx N.V. (NASDAQ:IFRX) stands against the other German stocks. In Germany, the economic growth is based on industry. According to Deutschland.de, Germany’s manufacturing industry contributed 26.6% to the country’s gross […]

Insider Monkey last month

IFRX
InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of GOHIBIC (vilobelimab), under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respirato

GlobeNewswire last month

IFRX
Prenetics Global And 2 Other US Penny Stocks To Watch

As the post-election stock market rally loses steam, major indexes in the United States have shown mixed results, reflecting investor uncertainty amid fluctuating interest rates and inflation data. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential value and growth opportunities. Though the term "penny stocks" may seem outdated, these investments can still offer unique prospects when backed by strong financials...

Simply Wall St. last month

PRE

PRENW

IFRX
InflaRx Reports Q3 2024 Financial Results and Progress

Inflarx N.V. ( (IFRX) ) has released its Q3 earnings. Here is a breakdown of the information Inflarx N.V. presented to its investors. InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics, particularly targeting the complement system, with its lead product candidate being vilobelimab. The company recently released its third-quarter 2024 financial results, showcasing significant milestones in their clinical trials and ongoing financial stability. Key hig

TipRanks last month

IFRX
We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 2 months ago

IFRX
InflaRx expects cash to fund operations into 2026

As of September 30, 2024, InflaRx’s (IFRX) total available funds amounted to EUR 62.0 million, composed of EUR 26.2 million in cash and cash equivalents and EUR 35.8 million in marketable securities. From the EUR 26.2 million cash and cash equivalents, EUR 4.2 million are held in EURO and EUR 24.6 million are held in USD, this is equivalent to EUR 22.0 million at an exchange rate of 1.1196 on 30 September 2024. All marketable securities are held in USD and have a nominal value of $40.5 million.

TipRanks 2 months ago

IFRX
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates

InflaRx (IFRX) delivered earnings and revenue surprises of -22.22% and 195.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

IFRX
InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025InflaRx pipeline highlighted at multiple medical congresses, including vilobelimab in COVID-19 and hidradenitis suppurativa (HS) and INF904Phase 2a trial for INF904 expected to initiate by year-end 2024, with first data readout expected in summer 2025European Committee for Medicinal Produc

GlobeNewswire 2 months ago

IFRX
InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third quarter 2024 financial and operating results on Friday, November 8, 2024, before the market opens. No conference call is planned. In addition, InflaRx will participate in the following investor event: Guggenheim Securities Inaugural Healthcare Innovation Confer

GlobeNewswire 2 months ago

IFRX
InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, September 25 – 28, 2024. Camilla Chon

GlobeNewswire 3 months ago

IFRX
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company’s novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. Members of InflaRx leadership also participated in a satellite symposium highlighting the

GlobeNewswire 4 months ago

IFRX
InflaRx Announces Participation in September Investor Events

JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9-11, 2024 in New York, NY InflaRx’s on-demand virtual presentation for the conference will be available beginning on September 9th. Infla

GlobeNewswire 4 months ago

IFRX
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

InflaRx (IFRX) delivered earnings and revenue surprises of -23.81% and 83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

IFRX
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Hosted research and development (R&D) event focused on the differentiation of INF904 and its potential in addressing significant unmet needs in inflammation & immunology (I&I)Initiation of a Phase 2a study with INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by year-end 2024First Phase 2a data readout for INF904 expected in the summer of 2025, with Phase 2b trial initiation expected in 2025Interim analysis for vilobelimab Phase 3 trial in pyoderma gangren

GlobeNewswire 5 months ago

IFRX
InflaRx to Report Second Quarter 2024 Results on August 8, 2024

JENA, Germany, Aug. 01, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its second quarter 2024 financial and operating results on August 8, 2024, before the market opens. No conference call is planned. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a an

GlobeNewswire 5 months ago

IFRX
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it will present preclinical data on the company’s novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. In addition to two poster presentations, InflaRx representatives will participate in a C5a/C5aR

GlobeNewswire 5 months ago

IFRX
Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

PREMIUM
MT Newswires 6 months ago

ALNY

IFRX

NVO

Performance Overview

Return	IF0.MU	S&P 500
YTD	-9.91%	-1.35%
1-Year	+28.81%	+22.51%
3-Year	-40.86%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InflaRx NV (IF0.MU)

InflaRx Announces Participation in January Events in San Francisco

US Penny Stocks To Watch In December 2024

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now?

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Prenetics Global And 2 Other US Penny Stocks To Watch

InflaRx Reports Q3 2024 Financial Results and Progress

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

InflaRx expects cash to fund operations into 2026

InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

InflaRx Announces Participation in September Investor Events

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Performance Overview